MTOR and breast carcinoma: ,31 As PI3K-Akt-mTOR signaling relate to proliferation, and tumor growth and invasion is a major effector of HER2 activity, the blockade of the PI3K signaling pathway by trastuzumab suppresses tumor growth in multiple models of HER2-overexpressing breast cancer.32